» Articles » PMID: 15760918

Extracellular Protease MRNAs Are Predominantly Expressed in the Stromal Areas of Microdissected Mouse Breast Carcinomas

Overview
Journal Carcinogenesis
Specialty Oncology
Date 2005 Mar 12
PMID 15760918
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Solid tumors synthesize a number of extracellular matrix-degrading proteases that are important for tumor progression. Based on qualitative in situ hybridization studies in human cancer tissue, a range of components involved in proteolysis appear to be expressed by stromal cells rather than cancer cells. We have now used laser capture microdissection and real-time PCR to quantify the mRNA expression of components of matrix-degrading proteolytic systems in cancer and stromal areas of mouse mammary tumors genetically induced by the polyoma virus middle T (PyMT) antigen. We examined the mRNA levels of urokinase plasminogen activator, plasminogen activator inhibitor 1 and the matrix metalloproteases MMP-2, -3, -11, -13 and -14, and found that all these seven genes are predominantly expressed by stromal cells. Our results were qualitatively supported by in situ hybridization analysis of the expression of mRNAs for MMP-2, -3 and -13 in the PyMT tumors. Statistical analyses indicated that the quantitative expression patterns observed in cancer and stromal cells isolated from individual tumors from different PyMT mice are quite reproducible. The methodology described in this study provides excellent tools to study the possible interactions between cancer and stromal cells during the development of breast cancer, and the results suggest that stromal cells are involved in carcinogenesis and tumor progression, which may have important implications for the biology and therapy of cancer.

Citing Articles

Myeloid Cells in Metastasis.

Swierczak A, Pollard J Cold Spring Harb Perspect Med. 2019; 10(5).

PMID: 31548218 PMC: 7197422. DOI: 10.1101/cshperspect.a038026.


Characterization of CADD522, a small molecule that inhibits RUNX2-DNA binding and exhibits antitumor activity.

Kim M, Gernapudi R, Choi E, Lapidus R, Passaniti A Oncotarget. 2017; 8(41):70916-70940.

PMID: 29050333 PMC: 5642608. DOI: 10.18632/oncotarget.20200.


Interferon-γ protects first-trimester decidual cells against aberrant matrix metalloproteinases 1, 3, and 9 expression in preeclampsia.

Lockwood C, Basar M, Kayisli U, Guzeloglu-Kayisli O, Murk W, Wang J Am J Pathol. 2014; 184(9):2549-59.

PMID: 25065683 PMC: 4188280. DOI: 10.1016/j.ajpath.2014.05.025.


Anti-matrix metalloproteinase-9 DNAzyme decreases tumor growth in the MMTV-PyMT mouse model of breast cancer.

Hallett M, Teng B, Hasegawa H, Schwab L, Seagroves T, Pourmotabbed T Breast Cancer Res. 2013; 15(1):R12.

PMID: 23407024 PMC: 3672740. DOI: 10.1186/bcr3385.


DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer.

Chen M, Shabashvili D, Nawab A, Yang S, Dyer L, Brown K Mol Cancer Ther. 2011; 11(2):370-82.

PMID: 22203734 PMC: 7457145. DOI: 10.1158/1535-7163.MCT-11-0458.